pharma news today obesity drugs glp-1 today Drug Market: the rapid growth of the diabetes and market Pfizer moves forward with weight-loss

However, many patients regain weight after stopping these medications and hence discussion needs to happen with your healthcare provider before stopping so that other interventions including diet and exercise are optimized

It is involving the endocrine cells of the gastrointestinal tract and their action as a possible therapeutic target for Type 2 Diabetes Mellitus due to their activation of GLP-1, which results in a hypoglycemic impact [17]

Data were selected for each complete year since the latest drug was marketed from 2018 quarter 1 to 2022 quarter 4

Diabetes Care 19 , 580586 (1996)

PPAR, peroxisome proliferator-activated receptor-

Mendelian randomization studies suggest reduced risks of schizophrenia, bipolar disorder, PTSD, and eating disorders in individuals treated with GLP-1RAs (203)